FDA warns that abuse and misuse of the OTC na...

FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) 

Listen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma ...  Show more

Osteoporosis in dialysis patients is a challenging yet crucial aspect of kidney care, often overshadowed by more familiar concerns. This episode of Life as a Nephrology Professional brings together experts to uncover the unique dynamics of bone disease in end-stage kidney disease ...  Show more

Question-based Review on Differential Diagnosis of Hypercalcemia (Pseudohypercalcemia, PTH-dependent vs PTH-independent Hypercalcemia) and Hypocalcemia; Vitamin D abnormalities, Abnormalities of Phosphate. Also discussed: Workup & Management of Humoral Hypercalcemia of Mal ...

Who’s really at risk for fractures, and how should we be treating them? Most fragility fractures occur in patients without osteoporosis. Should we rethink who gets treated? And could just one or two IV infusions (spread years apart) of zoledronate prevent fractures for years? Hav ...  Show more

Clarification of new evidence that Bisphosphonates for osteoporosis may actually weaken bones if people are left on them for too long ; Dietary change using FODMAPS to treat Irritable bowel syndrome when medicines have not worked; CRP testing for chest infections to identify whic ...  Show more